scholarly journals Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C

2020 ◽  
Vol 63 (2) ◽  
pp. 52-55 ◽  
Author(s):  
Yasser K. Rashed ◽  
Fatma A. Khalaf ◽  
Sobhy E. Kotb
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Thyroid Function ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Thyroid Function Tests ◽  
Pegylated Interferon Alpha ◽  
Function Tests

Background: Immunomodulatory properties of interferon (IFN) have been documented. It may induce autoimmune diseases such as autoimmune thyroiditis with hypo- or hyperthyroidism. In addition, it may impair thyroid hormone synthesis through affecting iodide organification in thyroid gland.Purpose: The aim of this study was to describe thyroid function tests disturbances in children with chronic hepatitis C (CHC) receiving pegylated interferon-alpha (PEG IFN-α) plus ribavirin.Methods: Fifty children with CHC virus infection who received combined pegylated interferon-alpha with ribavirin were selected. Other 50 apparently healthy children of matched age and sex (considered as control group) were selected. All children (100) were subject to liver function tests, virological studies, and follow-up of thyroid function test during and after the treatment course.Results: Our study showed that 28% of children received combined PEG IFN-α plus ribavirin showed subclinical hypothyroidism. After 24 weeks treatment with combined therapy of IFN plus ribavirin, the mean level of thyroid stimulating hormone (TSH) was 3.23±88 mU/mL, while TSH was 1.16± 0.77 mU/mL before starting treatment. On the other hand, mean TSH was 1.09±0.92 mU/mL in normal control group.Conclusion: This study revealed an association between subclinical thyroid dysfunction and treatment with IFN-alpha and ribavirin in children. Further studies on larger number of patients and longer follow-up duration are recommended for further confirmation.

Sex differences in depressive symptomatology in patients with chronic hepatitis C during pegylated interferon alpha therapy: A 72-week prospective study

2016 ◽  
Vol 33 (S1) ◽  
pp. S80-S80
Author(s):  
Z. Pavlovic ◽  
M. Jasovic-Gasic ◽  
D. Delic ◽  
N. Maric ◽  
O. Vukovic ◽  
...  
Keyword(s):  
Sex Differences ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Depressive Symptomatology ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Prevalence Of Depression

IntroductionTreatment with pegylated interferon alpha (PEG-IFN-α) is associated with depression more frequently in chronic hepatitis C (CHC) patients than with other inflammatory diseases.ObjectivesTo prospectively asses sex differences in the prevalence of depression in CHC patients during the PEG-IFN-α, as well as in the CHC group with no therapy.MethodsSample consisted of 103 subjects with CHC on the PEG-IFN-α and 103 subjects with CHC without interferon therapy. The diagnosis of depressive disorder was established by using Structured Clinical Interview and Criteria of International Classification Disorder. The severity of depression was assessed by using Hamilton Depression Rating Scale (HAMD ≥ 8) prior to PEG-IFN-α (baseline) and at the follow-up visits (4th, 12th, 24th, 48th, 72nd week).ResultsDuring the course of PEG-IFN-α, 49.5% of subjects showed depressive symptomatology (HAMD ≥ 8). Except at baseline and in the 72nd week, on the all other follow-up visits the prevalence of depression was significantly higher in female subjects (*all Ps < 0.05). The strongest difference was observed in the 12th week: of all the subjects with HAMD ≥ 8, 68.8% were female and 32.7% were male (P < 0.001). The multivariate logistic regression model showed that female sex is a very strong predictor for the development of depression during the interferon treatment [Exp (B) = 6.729]. There were no significant sex differences in the prevalence of depression in the control group.ConclusionsOur study (the longest study in this area) indicate that the prevalence of depression is significantly higher in female subjects with CHC during antiviral treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Pegylated interferon alpha 2b for chronic hepatitis C

2009 ◽  
Author(s):  
Tahany Awad ◽  
Kristian Thorlund ◽  
Goran Hauser ◽  
Mahasen Mabrouk ◽  
Davor Stimac ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B

scholarly journals Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C

2016 ◽  
Vol 67 (5) ◽  
pp. 272 ◽  
Author(s):  
June Seok Song ◽  
Joo Hyun Sohn ◽  
Jae Yoon Jeong ◽  
Ji-Hee Min ◽  
Won Seok Choi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha

Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment

2006 ◽  
Vol 37 (4) ◽  
pp. 329-331 ◽  
Author(s):  
Ioannis S. Elefsiniotis ◽  
Aikaterini Petrocheilou ◽  
Nikolaos Scarmeas ◽  
Ioannis Ketikoglou ◽  
Konstantinos D. Pantazis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Chronic Hepatitis C Patients
Sign in / Sign up

Export Citation Format

Share Document